Loading...

China Oncology

29 February 2024, Volume 34 Issue 2
Specialist' Commentary

Progress of important clinical research of breast cancer in China in 2023

ZHANG Qi, XIU Bingqiu, WU Jiong

2024, 34 (2): 135-142. doi: 10.19401/j.cnki.1007-3639.2024.02.001

Abstract ( 178) PDF (1216KB) ( 318 ) HTML ( 17 )

Important research progress in clinical practice for advanced breast cancer in 2023

ZHANG Siyuan, JIANG Zefei

2024, 34 (2): 143-150. doi: 10.19401/j.cnki.1007-3639.2024.02.002

Abstract ( 96) PDF (1152KB) ( 204 ) HTML ( 10 )

Important research progress in clinical practice for early breast cancer in 2023

WANG Zhaobu, LI Xing, YU Xinmiao, JIN Feng

2024, 34 (2): 151-160. doi: 10.19401/j.cnki.1007-3639.2024.02.003

Abstract ( 87) PDF (1214KB) ( 211 ) HTML ( 6 )

Article

Efficacy, metabolic characteristics, safety and immunogenicity of AK-HER2 compared with reference trastuzumab in patients with metastatic HER2-positive breast cancer: a multicenter, randomized, double-blind phase Ⅲ equivalence trial

LUO Yang, SUN Tao, SHAO Zhimin, CUI Jiuwei, PAN Yueyin, ZHANG Qingyuan, CHENG Ying, LI huiping, YANG Yan, YE Changsheng, YU Guohua, WANG Jingfen, LIU Yunjiang, LIU Xinlan, ZHOU Yuhong, BAI Yuju, GU Yuanting, WANG Xiaojia, XU Binghe, SONG Lihua

2024, 34 (2): 161-175. doi: 10.19401/j.cnki.1007-3639.2024.02.004

Abstract ( 71) PDF (1342KB) ( 172 ) HTML ( 6 )

KDM4A promotes the migration and invasion of breast cancer cell line MDA-MB-231 by downregulating BMP9

CHEN Yuanxiang, YU Tao, YANG Shiyu, ZENG Tao, WEI Lan, ZHANG Yan

2024, 34 (2): 176-184. doi: 10.19401/j.cnki.1007-3639.2024.02.005

Abstract ( 50) PDF (1638KB) ( 241 ) HTML ( 8 )

Impact of BRCA1/2 germline mutation on the incidence of second primary cancer following postoperative radiotherapy in patients with triple-negative breast cancer

HU Xiaoyu, CAI Yuwen, YE Fugui, SHAO Zhimin, HU Weigang, YU Keda

2024, 34 (2): 185-190. doi: 10.19401/j.cnki.1007-3639.2024.02.006

Abstract ( 59) PDF (1047KB) ( 240 ) HTML ( 4 )

Influencing factors and establishment of a prediction model for the tumor regression after neoadjuvant chemoradiotherapy in locally advanced rectal cancer

LIU Zhiyu, XU Dong, CHEN Xihao, LI Jipeng

2024, 34 (2): 191-200. doi: 10.19401/j.cnki.1007-3639.2024.02.007

Abstract ( 39) PDF (1138KB) ( 231 ) HTML ( 6 )

Review

Research progress on the correlation between imaging features and the molecular subtype, histopathology, clinical prognosis of ductal carcinoma in situ of the breast

LIU Qi, CHANG Cai, LI Jiawei

2024, 34 (2): 201-209. doi: 10.19401/j.cnki.1007-3639.2024.02.008

Abstract ( 77) PDF (1165KB) ( 210 ) HTML ( 2 )

Application progress and challenges of artificial intelligence in organoid research

WU Hongji, WANG Haixia, WANG Ling, LUO Xiaogang, ZOU Dongling

2024, 34 (2): 210-219. doi: 10.19401/j.cnki.1007-3639.2024.02.009

Abstract ( 73) PDF (1165KB) ( 234 ) HTML ( 10 )

Guideline and Concensus

Expert consensus on population-based BRCA germline mutation screening in China (2024 edition)

China Anti-Cancer Association Tumor Biomarker Professional Committee, Shanghai Anti-Cancer Association Tumor Biomarker Professional Committee

2024, 34 (2): 220-238. doi: 10.19401/j.cnki.1007-3639.2024.02.010

Abstract ( 187) PDF (1336KB) ( 471 ) HTML ( 24 )

中国癌症杂志
    Database Indexing
  • A Guide to the Core Journals of China
  • Chinese Science Citation Database (CSCD)
  • China National Knowledge Infrastructure (CNKI)
  • Chinese Sci-tech Paper and Citation Database (CSTPCD)
  • Outsanding S&T Journals of China (2020) (F5000)
  • World Journal Clout Index (WJCI) Report of Scientific and Technological Periodicals (2021)
  • SCOPUS
  • EMBASE
  • DOAJ
  • Chemical Abstracts (CA)
  • Japan Science and Technology Database (JST)
  • The Western Pacific Region Index Medicus (WPRIM)
  • EBSCO
  • Index of Copernicus International (ICI)

Competent Authorities

 The Ministry of Education of the People’s Republic of China

Sponsored by

 Fudan University Shanghai Cancer Center

Edited by

 Editorial Board of China Oncology

Editor-in-Chief

 SHAO Zhimin

Honorary Editor-in-Chief

 TANG Zhaoyou, CAO Shilong, SHEN Zhenzhou

Printed by

 Shanghai Ouyang Printing Co., Ltd.

WeChat